Makers Laboratories Past Earnings Performance
Past criteria checks 2/6
Makers Laboratories's earnings have been declining at an average annual rate of -36.1%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 15.7% per year. Makers Laboratories's return on equity is 6.2%, and it has net margins of 4.4%.
Key information
-36.1%
Earnings growth rate
-34.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 15.7% |
| Return on equity | 6.2% |
| Net Margin | 4.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Makers Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,135 | 50 | 146 | 0 |
| 30 Jun 24 | 1,090 | -52 | 146 | 0 |
| 31 Mar 24 | 1,044 | -63 | 144 | 0 |
| 31 Dec 23 | 1,060 | -53 | 137 | 0 |
| 30 Sep 23 | 994 | -59 | 132 | 0 |
| 30 Jun 23 | 1,008 | -52 | 126 | 0 |
| 31 Mar 23 | 1,013 | -48 | 121 | 0 |
| 31 Dec 22 | 1,009 | -51 | 123 | 0 |
| 30 Sep 22 | 1,105 | -8 | 125 | 0 |
| 30 Jun 22 | 1,176 | 15 | 126 | 0 |
| 31 Mar 22 | 1,282 | 50 | 128 | 0 |
| 31 Dec 21 | 1,322 | 58 | 126 | 0 |
| 30 Sep 21 | 1,169 | 23 | 113 | 0 |
| 30 Jun 21 | 964 | 15 | 102 | 0 |
| 31 Mar 21 | 686 | -3 | 90 | 0 |
| 31 Dec 20 | 502 | -2 | 81 | 0 |
| 30 Sep 20 | 466 | 11 | 80 | 0 |
| 30 Jun 20 | 503 | 5 | 82 | 0 |
| 31 Mar 20 | 514 | -1 | 82 | 0 |
| 31 Dec 19 | 468 | 3 | 79 | 0 |
| 30 Sep 19 | 457 | 3 | 78 | 0 |
| 30 Jun 19 | 427 | 9 | 76 | 0 |
| 31 Mar 19 | 466 | 24 | 74 | 0 |
| 31 Dec 18 | 521 | 25 | 75 | 0 |
| 30 Sep 18 | 560 | 33 | 71 | 0 |
| 30 Jun 18 | 589 | 42 | 66 | 0 |
| 31 Mar 18 | 559 | 31 | 66 | 0 |
| 31 Dec 17 | 568 | 22 | 64 | 0 |
| 30 Sep 17 | 558 | 27 | 65 | 0 |
| 30 Jun 17 | 566 | 21 | 68 | 0 |
| 31 Mar 17 | 578 | 37 | 67 | 0 |
| 31 Dec 16 | 582 | 31 | 80 | 0 |
| 30 Sep 16 | 582 | 27 | 81 | 0 |
| 30 Jun 16 | 567 | 21 | -2 | 0 |
| 31 Mar 16 | 614 | 23 | 81 | 0 |
| 31 Dec 15 | 608 | 27 | 145 | 0 |
| 30 Sep 15 | 630 | 29 | 145 | 0 |
| 30 Jun 15 | 653 | 31 | 147 | 0 |
| 31 Mar 15 | 649 | 24 | 72 | 0 |
| 31 Dec 14 | 675 | 16 | 155 | 0 |
| 30 Sep 14 | 666 | 8 | 154 | 0 |
| 30 Jun 14 | 686 | 8 | 154 | 0 |
| 31 Mar 14 | 683 | 6 | 158 | 0 |
| 31 Dec 13 | 681 | 21 | 146 | 0 |
Quality Earnings: 506919 has high quality earnings.
Growing Profit Margin: 506919 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 506919's earnings have declined by 36.1% per year over the past 5 years.
Accelerating Growth: 506919 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 506919 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.5%).
Return on Equity
High ROE: 506919's Return on Equity (6.2%) is considered low.